Literature DB >> 11206463

Design, synthesis, and biological evaluation of HIV/FIV protease inhibitors incorporating a conformationally constrained macrocycle with a small P3' residue.

C C Mak1, V D Le, Y C Lin, J H Elder, C H Wong.   

Abstract

A series of norstatine-based HIV/FIV protease inhibitors incorporating a 15-membered macrocycle as a mimic of the tripeptide (Ala-Val-Phe), a motif with a small P3' residue elective against the FIV protease and the drug-resistant HIV proteases, has been synthesized. It was found that the macrocycle is important to the overall activity of the inhibitors. Certain inhibitors were developed expressing low nanomolar inhibitory activity against the HIV/FIV proteases and they are also effective against some drug-resistant as well as TL3-resistant HIV proteases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11206463     DOI: 10.1016/s0960-894x(00)00641-7

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.

Authors:  Ying-Chuan Lin; Ashraf Brik; Aymeric de Parseval; Karen Tam; Bruce E Torbett; Chi-Huey Wong; John H Elder
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

2.  Generation of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease.

Authors:  Ying-Chuan Lin; Bruce E Torbett; John H Elder
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

3.  Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.

Authors:  Holly Heaslet; Ying-Chuan Lin; Karen Tam; Bruce E Torbett; John H Elder; C David Stout
Journal:  Retrovirology       Date:  2007-01-09       Impact factor: 4.602

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.